Brokerages expect that Theravance Biopharma Inc (NASDAQ:TBPH) will announce earnings per share (EPS) of ($1.13) for the current quarter, according to Zacks. Three analysts have made estimates for Theravance Biopharma’s earnings, with the highest EPS estimate coming in at ($0.86) and the lowest estimate coming in at ($1.37). Theravance Biopharma reported earnings of ($1.64) per share in the same quarter last year, which suggests a positive year over year growth rate of 31.1%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Theravance Biopharma will report full-year earnings of ($4.18) per share for the current financial year, with EPS estimates ranging from ($4.45) to ($3.93). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.53) per share, with EPS estimates ranging from ($5.57) to ($3.56). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.18) by $0.08. The company had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative net margin of 513.41% and a negative return on equity of 505.90%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Group AG raised its position in Theravance Biopharma by 88.4% in the first quarter. UBS Group AG now owns 4,511 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 2,117 shares during the period. United Services Automobile Association bought a new position in Theravance Biopharma in the third quarter worth approximately $210,000. Xact Kapitalforvaltning AB bought a new position in Theravance Biopharma in the third quarter worth approximately $285,000. Man Group plc bought a new position in Theravance Biopharma in the third quarter worth approximately $292,000. Finally, Engineers Gate Manager LP bought a new position in Theravance Biopharma in the third quarter worth approximately $662,000. Institutional investors and hedge funds own 83.98% of the company’s stock.
Shares of Theravance Biopharma stock opened at $26.41 on Friday. The company has a market cap of $1.46 billion, a P/E ratio of -4.85 and a beta of 2.12. Theravance Biopharma has a twelve month low of $21.27 and a twelve month high of $35.48. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.08 and a current ratio of 3.26.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
Recommended Story: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.